Epigenetic drug reverses Alzheimer’s memory loss in mice, UB study shows

University of Barcelona researchers report that FLAV-27, a first-in-class SAM-competitive G9a inhibitor, reverses cognitive deficits in multiple Alzheimer’s disease mouse models by reprogramming neuronal gene activity, a mechanism distinct from beta-amyloid–targeting drugs; the compound is currently in preclinical stages and could represent a disease-modifying approach pending human safety data.